Defence Therapeutics (DTCFF) News Today $0.41 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Defence Therapeutics Welcomes Radiopharmaceutical ExpertNovember 15, 2024 | markets.businessinsider.comDefence Therapeutics Launches Convertible Debenture OfferingNovember 15, 2024 | markets.businessinsider.comDefence Therapeutics Inc.: Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of DirectorsNovember 13, 2024 | finanznachrichten.deDefence Therapeutics Inc. (DTC.F)August 20, 2024 | ca.finance.yahoo.comDefence Therapeutics Inc. (DTCFF)July 30, 2024 | finance.yahoo.comDefence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline GrowthApril 17, 2024 | finance.yahoo.comDefence Therapeutics Inc.: Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing UpdateFebruary 29, 2024 | finanznachrichten.deDefence Therapeutics Completes 1st Tranche of FinancingJanuary 30, 2024 | finance.yahoo.comDefence FinancingJanuary 19, 2024 | finance.yahoo.comDefence Begins Trading on the OTCQB and Arranges FinancingJanuary 13, 2024 | finance.yahoo.comDefence Therapeutics Inc DTCFFJanuary 10, 2024 | morningstar.comRETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)December 12, 2023 | finance.yahoo.comDefence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)December 11, 2023 | finance.yahoo.comDefence's Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid TumorsNovember 14, 2023 | finance.yahoo.comDefence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine TechnologyNovember 7, 2023 | finance.yahoo.comDefence Therapeutics Inc.: Defence to Collaborate with Native Ads for Marketing CampaignOctober 27, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, SwitzerlandOctober 26, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA VaccinesOctober 26, 2023 | finanznachrichten.deDefence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking PlatformOctober 25, 2023 | finance.yahoo.comDefence Therapeutics Inc (DTC)October 22, 2023 | investing.comDefence's Novel Accutox(TM) Continues to Surprise on Results Against CancerOctober 18, 2023 | finance.yahoo.comBristol Myers Squibb Enters the Multi-Billion-Dollar Oncology RaceOctober 17, 2023 | theglobeandmail.comDefence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid LymphomaOctober 17, 2023 | finance.yahoo.comElli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology RaceOctober 11, 2023 | theglobeandmail.comDefence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer ScienceOctober 10, 2023 | finance.yahoo.comDefence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, SwitzerlandOctober 6, 2023 | finance.yahoo.comDefence Therapeutics Inc.: Defence's Innovative Therapeutics Featured on Viewpoint with Dennis QuaidSeptember 28, 2023 | finanznachrichten.deDefence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA VaccinesSeptember 25, 2023 | finance.yahoo.comDefence to Collaborate with Native Ads for Marketing CampaignSeptember 22, 2023 | finance.yahoo.comSelf-defense classes for women hit the mark in North PortSeptember 14, 2023 | yahoo.comDefence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer TherapeuticsSeptember 12, 2023 | finance.yahoo.comUkraine's Defence Intelligence chief announces forthcoming attacks in CrimeaSeptember 8, 2023 | news.yahoo.comDefence Successfully Completes the First Milestone of Its Collaboration Agreement with OranoJuly 18, 2023 | finance.yahoo.comRETRANSMISSION: Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in BiotechnologyJuly 5, 2023 | finance.yahoo.comDefence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in BiotechnologyJuly 4, 2023 | finance.yahoo.comDefence Therapeutics Inc.: DEFENCE PATENT PORTFOLIO AT THE FOREFRONT OF SUCCESSJune 28, 2023 | uk.movies.yahoo.comDefence Patent Portfolio at the Forefront of SuccessJune 28, 2023 | finance.yahoo.comDEFENCE’S PROPRIETARY ACCUM(TM) TECHNOLOGY FOR DELIVERY OF CRISPR/CAS GENOME-EDITING COMPLEXES PATENT APPLICATON PUBLISHEDJune 20, 2023 | uk.movies.yahoo.comDefence Therapeutics Inc.: Defence's Proprietary Accum Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application PublishedJune 20, 2023 | finanznachrichten.deDefence's Proprietary Accum(TM) Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application PublishedJune 20, 2023 | finance.yahoo.comDTC.MU - Defence Therapeutics IncJune 17, 2023 | ca.finance.yahoo.comDTCFF - Defence Therapeutics Inc.June 17, 2023 | ca.finance.yahoo.comDefence Therapeutics Inc.: Defence Manufacturing of AccuTox CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of HopeJune 16, 2023 | finanznachrichten.deDefence Manufacturing of AccuTox(TM) CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of HopeJune 16, 2023 | finance.yahoo.comDefence Begins Testing Its Arm Vaccine Against Pancreatic CancerJune 6, 2023 | finance.yahoo.comDefence Therapeutics Inc.: DEFENCE BEGINS TESTING ITS ARM VACCINE AGAINST PANCREATIC CANCERJune 6, 2023 | uk.news.yahoo.comDefence Therapeutics Inc.: Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 MillionMay 26, 2023 | finanznachrichten.deDefence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 MillionMay 26, 2023 | finance.yahoo.comDefence Therapeutics Inc.: Defence Granted US Patent with Broad Coverage on Accum-based Vaccine Enhancer Platform TechnologyMay 26, 2023 | finanznachrichten.deDefence Therapeutics Inc.: Breakthrough Results: Defence's Arm Vaccine Cured 100% of Animals with Pre-Established LymphomaMay 25, 2023 | finanznachrichten.de Get Defence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DTCFF and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now DTCFF Media Mentions By Week DTCFF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DTCFF News Sentiment▼0.200.47▲Average Medical News Sentiment DTCFF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DTCFF Articles This Week▼20▲DTCFF Articles Average Week Get Defence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DTCFF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News AXIM Biotechnologies News BerGenBio ASA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:DTCFF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Defence Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Defence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
